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Abstract
Background There is a high burden of antipsychotic use in residential aged care facilities (RACFs) and there is concern 
regarding potential inappropriate prescribing of antipsychotics in response to mild behavioural symptoms. Antipsychotic 
use has been associated with a higher risk of mortality in community-dwelling older adults with dementia, but few studies 
have examined associations upon RACF entry.
Aims To examine associations between incident antipsychotic use and risk of mortality for people with and without diag-
nosed dementia in RACFs.
Methods A retrospective cohort study, employing a new-user design (individuals did not receive an antipsychotic 6 months 
before enrolment) of 265,820 people who accessed RACFs in Australia between 1/4/2008 and 30/6/2015 was conducted. 
Cox regression models were used to examine adjusted associations between antipsychotic use in the first 100 days of RACF 
entry and mortality.
Results In the 100 days after entering care, 29,455 residents (11.1%) were dispensed an antipsychotic. 180,956 (68.1%) 
residents died [38,249 (14.4%) were related to cerebrovascular causes] over a median 2.1 years (interquartile range 1.0–3.6) 
follow-up. Of the residents included, 119,665 (45.0%) had a diagnosis of dementia. Incident antipsychotic use was associated 
with higher risk of mortality in residents with dementia (adjusted hazard ratio 1.20, 95% confidence interval 1.18–1.22) and 
without dementia (1.28, 1.24–1.31).
Conclusion Initiation of antipsychotics after moving to RACFs is associated with a higher risk of mortality. Careful consid-
eration of the potential benefits and harms should be given when starting a new prescription for antipsychotics for people 
moving to RACFs.
Keywords Antipsychotics · Dementia · Mortality · Nursing homes
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Introduction
Moving to residential aged care facilities (RACFs) can 
be a distressing time due to the major lifestyle change of 
moving to an unfamiliar setting, separation from fam-
ily members, and potential issues regarding privacy and 
independence [1]. There is a high prevalence of subopti-
mal medicine prescribing in older adults which have been 
associated with poorer outcomes including increased hos-
pitalisations and mortality [2]. For older adults living in 
RACFs, exposure to potentially inappropriate medicines is 
high and associated with poorer quality of life [3]. Approx-
imately half of older people moving to RACFs in Australia 
have dementia, [4] and behavioural symptoms such as agi-
tation and aggression, may increase during a move [5]. 
Pharmacological approaches to managing behaviours for 
people with dementia include the use of antipsychotics, 
despite limited effectiveness for this use and the potential 
for serious adverse events, including mortality [6]. These 
adverse effects must be considered when determining the 
appropriateness of prescribing antipsychotics to residents 
and non-pharmacological approaches are preferred [6, 7].
In Australia, an antipsychotic may be indicated for 
short-term use among people with dementia when the per-
son has severe agitation and aggression associated with 
risk of harm, delusions and hallucinations or comorbid 
pre-existing mental health conditions and does not respond 
to non-pharmacological approaches [8]. Similar guidelines 
for prescribing antipsychotics for people with dementia 
exist in countries such as the United States (US) and Can-
ada [9, 10]. Despite such guidelines, there are concerns 
that antipsychotics are used inappropriately in response to 
mild behavioural symptoms such as wandering, insomnia 
or uncooperativeness [11]. A recent study of Australian 
RACFs estimated that 22% of residents were prescribed 
antipsychotics which is similar to the prevalence reported 
in US long-stay nursing homes [12, 13].
Antipsychotic use for people with dementia has been 
associated with a higher risk of serious adverse events, 
including extrapyramidal symptoms, worsening cogni-
tive function, falls, cerebrovascular complications, stroke 
and premature mortality [14–16] After the publication of 
a meta-analysis of randomised placebo-controlled trials 
concluded atypical antipsychotics were associated with a 
small increased risk of death for people with dementia, 
the US Food and Drug Administration (FDA) issued an 
advisory warning in 2005 [17]. This advisory warning was 
extended to typical antipsychotics in 2008 [18]. Obser-
vational studies have suggested the use of typical antip-
sychotics may have a similar or higher risk of mortality 
for people with dementia compared to atypical antipsy-
chotics, [19–21] whereas a meta-analysis of randomised 
placebo-controlled trials did not find any evidence to show 
an association between typical antipsychotics and mortal-
ity risk [22]. When examining associations between antip-
sychotic use and mortality specifically for people living in 
RACFs, fewer studies have been specifically undertaken in 
RACFs, and some variation has been noted. For example, 
some studies have shown an association between antipsy-
chotic use and higher risk of mortality [23, 24] and others 
have suggested no association [25, 26]. In this study, we 
aim to examine associations between incident antipsy-
chotic use and risk of mortality for people with and with-
out diagnosed dementia in RACFs in Australia.
Methods
Study design, setting, and data sources
A national study was conducted using the Registry of Senior 
Australians (ROSA), which captures comprehensive data for 
all older people who have accessed government-subsidised 
aged care services in Australia. In ROSA, de-identified data 
collected during aged care eligibility assessments are linked 
to information on the types of aged care services the per-
son received, and assessments performed after moving to 
a RACF [27].
Aged care eligibility assessments are conducted by a team 
of medical and allied health professionals who collect infor-
mation in an interview about the person’s sociodemographic 
characteristics, carer information and physical and psycho-
logical health to determine which type of aged care services 
are appropriate for the individual [28]. The aged care eligi-
bility assessments can record up to ten health conditions, 
which are coded using a modified International Statistical 
Classification of Disease and Related Health Problems-Tenth 
Revision-Australian Modification (ICD-10-AM) classifica-
tion [28]. In addition, individuals who move to a RACF 
undergo an assessment to assess their core care needs as a 
basis for allocating funding [29]. These assessments include 
detailed information about the person’s physical and psy-
chological health after moving to a RACF including health 
conditions, activities of daily living (ADLs), behaviour, cog-
nitive impairment and depression. The assessments list up 
to three health conditions and three mental and behavioural 
conditions including dementia and use the ICD-10-AM cod-
ing system.
The ROSA also contains details of all subsidised medi-
cations dispensed for recipients of aged care services via 
Australia’s national pharmaceutical subsidy schemes (the 
Pharmaceutical Benefits Scheme (PBS) and Repatriation 
PBS). Date and primary and other causes of death (clas-
sified according to the ICD-10-AM) are available from the 
linked National Death Index dataset.
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Study participants
The current study includes all people aged 65 years or older 
or aged 50 years or older if they identified as Aboriginal or 
Torres Strait Islander, who moved to government-subsidised 
RACFs between 1/04/2008 (the month after the entry into 
care assessment was introduced) and 30/06/2015.
Study participants were included if they resided in a 
RACF for > 100 days and had an assessment within 100 days 
of entry to aged care. The study adopted a ‘new-user design’ 
and excluded prevalent users of antipsychotics, which was 
defined as residents who had an antipsychotic dispensed in 
the 6 months prior to moving to a RACF. We also excluded 
residents who were not entitled to access government-
subsidised medical and pharmaceutical services to ensure 
full capture of subsidised medication use for all in the final 
cohort (n = 265,820). See Supplementary Fig. 1 for the study 
flow diagram.
Exposure of interest
Antipsychotic use in the first 100 days after RACF entry 
was the exposure of interest in this study. The World Health 
Organization (WHO) Anatomical Therapeutic Classification 
(ATC) System codes were used to identify dispensing for 
typical antipsychotics (ATC codes N05AA-N05AD, exclud-
ing N05AB04, and N05AF) and atypical antipsychotics 
(N05AE, N05AH, N05AL and N05AX) [30].
Outcome of interest
The primary outcome of interest was all-cause mortality 
and the secondary outcome of interest was mortality with 
cerebrovascular causes (ICD-10-AM codes I60-I69). Resi-
dents were followed until death or 31/12/2016, whichever 
occurred first.
Covariates
The following covariates were examined: age, sex and co-
morbidity score as determined from the Rx-Risk-V, a med-
ication-based co-morbidity measure [31]. The Rx-Risk-V 
includes 46 co-morbidities and has been validated in older 
populations and has been to shown to predict 1-year mortal-
ity. The following covariates were also examined from the 
assessment at entry into aged care, [29] which are all ranked 
on four levels according to independence with the activ-
ity or symptoms experienced: ADLs including nutrition, 
mobility, personal hygiene, toileting, continence, cognitive 
impairment determined from the Psychogeriatric Assess-
ment Scale-Cognitive Impairment Scale: PAS-CIS, wander-
ing, verbal behavioural symptoms and physical behavioural 
symptoms and depression determined from the Cornell 
Scale for Depression (CSD) and diagnosis of depression in 
previous 12 months.
Dementia was ascertained using the health conditions 
reported at the aged care eligibility and entry into care 
assessments (Supplementary Table 1) or if in the 6 months 
prior to moving to a RACF there was a dispensing history 
of acetylcholinesterase inhibitor (ATC codes N06DA02, 
N06DA03 and N06DA04) or memantine (ATC code 
N06DX01).
Statistical analyses
Descriptive statistics are presented by whether the residents 
were dispensed an antipsychotic in the first 100 days after 
moving to a RACF with frequencies and percentages for 
categorical variables and means and standard deviations 
(SDs) or medians and inter-quartile ranges (IQR) for con-
tinuous variables. The Kaplan–Meier method was used to 
estimate median survival time after the first 100 days of liv-
ing in a RACF. Cox multivariate regression models were 
used to estimate the risk of all-cause mortality associated 
with an antipsychotic use in the first 100 days after mov-
ing to a RACF compared with no antipsychotic use in the 
first 100 days for all residents and stratified by dementia 
status [32]. Age- and sex-adjusted hazard ratios (HRs) and 
95% confidence intervals were estimated. Final models were 
adjusted for all covariates described in the previous section. 
Proportional hazard assumptions were tested based on Sch-
oenfeld residuals after fitting the Cox model. Analyses were 
repeated to compare outcomes among residents exposed to 
typical versus atypical antipsychotics and to examine mor-
tality with cerebrovascular causes as a secondary outcome. 
Statistical analyses were performed using Stata v.15.0 (Stata 
Corp LP, College Station, TX, USA).
Ethical approval
This study received ethical approval from the University of 
South Australia (Protocol ID: 200489; Evaluating Healthy 
Ageing in Australia, 1997–2017) and from the Austral-
ian Institute of Health and Welfare’s Ethics Committee 
(EO2018/1/418; Evaluating Healthy Ageing in Australia, 
2002–2017). As the data were de-identified, informed con-
sent was not required in line with sought ethical approvals.
Results
Characteristics of the study cohort
Of the 265,820 residents included in this study, 65.0% 
were females, the mean age was 84.4 (SD = 6.9) years, 
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45.0% had diagnosed dementia and the median number 
of co-morbidities was 5 (IQR = 3–7). The median follow-
up of this cohort was 2.1 years (IQR = 1.0–3.6). In the 
cohort, 11.1% (n = 29,455) were newly dispensed at least 
one antipsychotic in the first 100 days after moving to a 
RACF. Of these residents, 15.2% (n = 4,469) had only typi-
cal antipsychotic(s) dispensed, 76.8% (22,617) had only 
atypical antipsychotic(s) dispensed, and 8.0% (n = 2,369) 
had both typical and atypical antipsychotics dispensed 
which could reflect concomitant use or switching. Of the 
residents who received antipsychotic(s), 76.1% were living 
with dementia compared to 41.2% of residents who did not 
receive antipsychotic(s), Table 1. Of the residents living with 
dementia 18.7% (n = 22,408) received an antipsychotic com-
pared to 4.8% (n = 7,047) of residents without dementia. The 
prevalence of use of each antipsychotic is shown in Supple-
mentary Table 2. Haloperidol was the most common typi-
cal antipsychotic dispensed (87.8% of residents dispensed 
typical antipsychotic(s) only) and risperidone was the most 
common atypical antipsychotic dispensed (77.8% of resi-
dents dispensed atypical antipsychotic(s) only).
Any antipsychotic use and risk of all‑cause mortality
Of the residents who received antipsychotic(s) in the first 
100 days after moving to a RACF, 73.8% died before the end 
of the follow-up period compared to 67.4% of residents not 
dispensed an antipsychotic.
After adjusting for age, sex, co-morbidity score, 
ADLs, cognitive impairment and behaviour needs, having 
antipsychotic(s) dispensed in the first 100 days after mov-
ing to a RACF was associated with a higher risk of mor-
tality compared with those who had no antipsychotic dis-
pensed (adjusted hazard ratio 1.22, 95% confidence interval 
1.20–1.24). This higher risk of mortality was consistent for 
residents without dementia (1.28, 1.24–1.31) and residents 
with dementia (1.20, 1.18–1.22), Table 2.
Typical and atypical antipsychotics and risk 
of all‑cause mortality
Typical (1.28, 1.24–1.33) and atypical (1.17, 1.15–1.19) 
antipsychotic use was independently associated with a 
higher risk of mortality in the cohort compared to those 
with no antipsychotics dispensed. Typical antipsychotic use 
was associated with a higher risk of mortality compared 
with residents dispensed atypical antipsychotics only (1.12, 
1.08–1.16).
For residents with dementia, being dispensed typi-
cal antipsychotic(s) (1.14, 1.10–1.20) and atypical 
antipsychotic(s) (1.17, 1.15–1.19) were independently 
associated with a comparable higher risk of mortality. For 
residents without dementia, typical antipsychotic use was 
associated with a higher risk of mortality compared with 
residents dispensed atypical antipsychotics only (1.33, 
1.25–1.42).
Antipsychotic use and risk of cerebrovascular 
mortality
In the cohort, 14.4% died with cerebrovascular causes 
(16.0% for residents dispensed antipsychotic(s) vs. 14.2% 
for residents not dispensed an antipsychotic). Antipsychotic 
use was associated with a higher risk of mortality with cer-
ebrovascular causes (1.17, 1.13–1.21). These associations 
were similar for atypical and typical antipsychotics and for 
residents with and without dementia, Table 2.
Discussion
This national study utilised data collected from all older peo-
ple moving to RACFs in Australia and demonstrated that 
incident use of antipsychotics was associated with a higher 
risk of all-cause mortality for residents with and without 
dementia. Typical and atypical medications were indepen-
dently associated with a higher risk of all-cause mortality 
and mortality with cerebrovascular causes. For residents 
without dementia, there was a higher risk of mortality 
associated with the use of typical antipsychotics compared 
to the use of atypical antipsychotics. Some of the associa-
tion between antipsychotics and mortality in this study was 
explained by the characteristics and health conditions of 
residents receiving antipsychotics, but the final models were 
adjusted for factors which may influence both antipsychotic 
use and mortality. In this study, 21,741 residents who newly 
received antipsychotics after moving to a RACF died within 
the study period. After adjusting for many potential con-
founding factors, the study showed a 22% higher risk of mor-
tality associated with incident antipsychotic use. Extrapola-
tion of these findings to the broader Australian population 
suggests 3921 deaths (95% confidence interval: 3624–4208) 
among residents of Australian RACFs could potentially be 
associated with the use of antipsychotics over 2 years.
Our findings are consistent with other observational 
studies and randomised controlled trials that have shown 
an association between antipsychotic use and higher risk 
of mortality for community-dwelling people with dementia 
[14, 17, 20, 21]. When examining the association between 
antipsychotics and mortality specifically for people living 
in RACFs, fewer studies have been conducted with some 
studies reporting no effect [25, 26, 33, 34]. Variations in 
study design should be considered as a possible contributing 
factor to inconsistencies. Some studies which have not found 
an association between antipsychotic use and mortality in 
RACFs have been conducted with relatively small sample 
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Table 1  Study participant characteristics and outcomes for all residents and stratified by incident antipsychotic use in first 100 days after moving 
to a residential aged care facility
All residents No antipsychotic(s) 
dispensed
At least one 
antipsychotic 
dispensed
Total, N (%) 265,820 (100) 236,365 (88.9) 29,455 (11.1)
Age (years), mean (SD) 84.4 (6.9) 84.6 (6.9) 82.8 (7.0)
Female, n (%) 172,815 (65.0) 156,506 (66.2) 16,309 (55.4)
Dementia, n (%) 119,665 (45.0) 97,257 (41.2) 22,408 (76.1)
Medication-based co-morbidity score, median (IQR) 5 (3–7) 5 (3–7) 4 (2–6)
Medication-based co-morbidity score > 5, n (%) 113,164 (42.6) 103,578 (43.8) 9,586 (32.5)
Cardiovascular medications
 IHD (angina or hypertension), n (%) 126,631 (47.6) 114,615 (48.5) 12,016 (40.8)
 Antihypertensives, n (%) 177,772 (44.3) 107,128 (45.3) 10,644 (36.1)
 Congestive heart failure, n (%) 53,050 (20.0) 49,097 (20.8) 3,953 (13.4)
 Hyperlipidaemia, n (%) 118,308 (44.5) 106,197 (44.9) 12,111 (41.1)
 Anticoagulants, n (%) 51,204 (19.3) 47,150 (20.0) 4,054 (13.8)
 Antiplatelets, n (%) 104,703 (39.4) 94,656 (40.1) 10,047 (34.1)
 ADLs, n (%)a
Nutrition
 1 = Lowest level (independent) 36,126 (13.6) 34,276 (4.5) 1,850 (6.3)
 2 90,449 (34.0) 82,489 (34.9) 7,960 (27.0)
 3 113,302 (42.6) 98,970 (41.9) 14,332 (48.7)
 4 = Highest level (physical assistance in all items) 25,943 (9.8) 20,630 (8.7) 5,313 (18.0)
Mobility
 1 = Lowest level (independent) 21,442 (8.1) 19,232 (8.1) 2,210 (7.5)
 2 34,309 (12.9) 31,250 (13.2) 3,059 (10.4)
 3 112,823 (42.4) 100,458 (42.5) 12,365 (42.0)
 4 = Highest level (physical assistance in all items) 97,246 (36.6) 85,425 (36.1) 11,821 (40.1)
Personal hygiene
 1 = Lowest level (independent) 5,987 (2.3) 5,752 (2.4) 235 (0.8)
 2 38,720 (14.6) 36,153 (15.3) 2,567 (8.7)
 3 57,394 (21.6) 53,415 (22.6) 3,979 (13.5)
 4 = Highest level (physical assistance in all items) 163,719 (61.6) 141,045 (59.7) 22,674 (77.0)
Toileting
 1 = Lowest level (independent) 44,711 (16.8) 42,280 (17.9) 2,431 (8.3)
 2 34,748 (24.4) 59,352 (25.1) 5,396 (18.3)
 3 35,335 (13.3) 31,216 (13.2) 4,119 (14.0)
 4 = Highest level (physical assistance in all items) 121,026 (45.5) 103,517 (43.8) 17,509 (59.4)
Continence
 1 = Lowest level (No incontinence) 89,535 (33.7) 83,513 (35.3) 6,022 (20.4)
 2 17,372 (6.5) 15,841 (6.7) 1,531 (5.2)
 3 20,300 (7.6) 18,239 (7.7) 2,061 (7.0)
 4 = Highest level (Incontinence > 3–4 times/week) 138,613 (52.2) 118,772 (50.3) 19,841 (67.4)
Behaviour, n (%)b
Cognitive  Skillsc
 1 = No/minimal impairment (PAS-CIS 0–3) 54,747 (20.6) 52,645 (22.3) 2,102 (7.1)
 2 = Mild impairment (PAS-CIS 4–9) 99,122 (37.3) 92,496 (39.1) 6,626 (22.5)
 3 = Moderate impairment (PAS-CIS 10–15) 72,920 (27.4) 62,457 (26.4) 10,463 (35.5)
 4 = Severe impairment (PAS-CIS 16–21) 39,031 (14.7) 28,787 (12.2) 10,264 (34.9)
Wandering
 1 = None or < 2 days/week 195,175 (73.4) 181,067 (76.6) 14,108 (47.9)
 Aging Clinical and Experimental Research
1 3
sizes, which may be underpowered to detect an association 
and others have not employed a new-user design [25, 26, 33, 
34]. A new-user design is preferable because including prev-
alent users of antipsychotics may introduce a survivor bias 
[35]. In the current study, we were able to employ a new-
user design by excluding people who had been dispensed 
an antipsychotic in the 6 months before moving to a RACF.
We determined that typical and atypical antipsychotic 
use were associated with a higher risk of cerebrovascular 
mortality in our cohort which is also in line with findings 
of previous studies [36]. Different mechanisms have been 
proposed to explain the higher risk of mortality associated 
with antipsychotic use. One such mechanism is that antipsy-
chotics have both direct effects on the vascular system (e.g. 
changes in blood pressure) and indirect effects (e.g. impaired 
endothelial function) [37].
In the current study, there was a higher proportion of 
residents dispensed antipsychotics living with dementia 
compared to those not dispensed antipsychotics. This is 
consistent with antipsychotics being utilised in RACFs 
to manage behavioural symptoms such as aggression and 
agitation, which may be more commonly experienced by 
people with dementia, often referred to as behavioural and 
psychological symptoms of dementia or BPSD [38]. How-
ever, there may be various other causes for the behaviours 
including responses to the change in environment, unmet 
needs (e.g. pain), delirium, or other external factors rather 
than being solely attributable to the underlying pathology 
of dementia [5, 38]. Antipsychotics are only indicated for 
people with dementia when the person has severe agitation 
and aggression associated with risk of harm, delusions and 
hallucinations or comorbid pre-existing mental health condi-
tions [8]. Non-pharmacological approaches tailored to the 
person’s preferences, skills and abilities should be trialled as 
a first-line approach [32]. For instance, recent research has 
suggested functional-analysis based interventions should be 
Table 1  (continued)
All residents No antipsychotic(s) 
dispensed
At least one 
antipsychotic 
dispensed
 2 = At least 2 days/week 25,857 (9.7) 22,300 (9.4) 3,557 (12.1)
 3 = At least 6 days/week 12,894 (4.9) 10,767 (4.6) 2,127 (7.2)
 4 =  ≥ Twice/day 6 days/week 31,894 (12.0) 22,231 (9.4) 9,663 (32.8)
Verbal behavioural symptoms
 1 = None or < 2 days/week 78,956 (29.7) 74,920 (31.7) 4,036 (13.7)
 2 = At least 2 days/week 52,723 (19.8) 48,123 (20.4) 4,600 (15.6)
 3 = At least 6 days/week 44,436 (16.7) 40,274 (17.0) 4,162 (14.1)
 4 =  ≥ Twice/day 6 days/week 89,705 (33.8) 73,048 (30.9) 16,657 (56.6)
Physical behavioural symptoms
 1 = None or < 2 days/week 124,862 (47.0) 118,743 (50.2) 6,119 (20.8)
 2 = At least 2 days/week 44,649 (16.8) 39,997 (16.9) 4,652 (15.8)
 3 = At least 6 days/week 28,373 (10.7) 24,777 (10.5) 3,596 (12.2)
 4 =  ≥ Twice/day 6 days/week 67,936 (25.6) 52,848 (22.4) 15,088 (51.2)
Depression
 1 = No or minimal symptoms (CSD 0–8) 141,610 (53.3) 128,792 (54.5) 12,818 (43.5)
 2 = Mild, moderate or major, no diagnosis (CSD 9–13 or CSD 14–38 
and no diagnosis)
73,424 (27.6) 64,494 (27.3) 8,930 (30.3)
 3 = Moderate and diagnosis (CSD 14–18 and diagnosis) 28,662 (10.8) 24,837 (10.5) 3,825 (13.0)
 4 = Major and diagnosis (CSD 19–38 and diagnosis) 22,124 (8.3) 18,242 (7.7) 3,882 (13.2)
Outcomes
All deaths within the study period, n (%) 180,956 (68.1) 159,215 (67.4) 21,741 (73.8)
Deaths within the study period with cerebrovascular causes, n (%) 38,249 (14.4) 33,535 (14.2) 4,714 (16.0)
Follow up time (years), Median (IQR) 2.1 (1.0–3.6) 2.1 (1.1–3.7) 1.7 (0.7–3.2)
Cardiovascular medication use defined using the Rx-Risk-V
ADLs activities of daily living, CSD Cornell Scale for Depression, IHD ischaemic heart disease, PAS-CIS Psychogeriatric Assessment Scale-
Cognitive Impairment Scale
a From the entry in to aged care assessment ADLs domain
b From the entry in to aged care assessment behaviour domain
c Assessment provides additional criteria if PAS-CIS was not deemed appropriate
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trialled as a first-line approach for behavioural symptoms 
for people with dementia due to similar effects for behav-
ioural symptoms as pharmacological approaches and lack of 
associated adverse events [7]. Antipsychotics are sometimes 
prescribed for short-term use in people experiencing dis-
tress associated with delirium and when symptoms cannot be 
resolved with non-pharmacological strategies, however, cau-
tion is advised as these medicines can also worsen delirium 
in older people [39].
Therapeutic use of music and/or dancing, support and 
counselling, reminiscence therapy or massage may also be 
beneficial, but approaches should always be person-centred 
[32].
After moving to a RACF, many residents consult a new 
general practitioner (GP) and medications may be dispensed 
by a different pharmacist [40]. Practitioners who have not 
had contact with the resident before may not be familiar 
with the usual behavioural symptoms of the resident which 
may result in potential overuse of antipsychotics. If antipsy-
chotic use is deemed necessary, individuals receiving antip-
sychotics should be monitored regularly, and an appropriate 
withdrawal strategy should be considered. Guidelines pro-
vide recommendations about assessing risks and benefits 
of antipsychotics, a plan to taper and withdraw the medica-
tion both in instances of no response and when an adequate 
response is seen [9]. It is possible to withdraw antipsychot-
ics in RACFs without worsening behaviours or an increase 
in adverse events using multidisciplinary approaches such 
as re-education and training of care staff and personalised 
deprescribing protocols [41–43].
Strengths and limitations of this study
This study utilised a large, nationally representative cohort 
of all people who accessed government-subsidised RACFs 
in Australia over a 7-year period. The study included com-
prehensive information collected by trained professionals 
about individuals accessing the aged care sector and their 
pharmaceutical and mortality information (including cause-
specific mortality). Due to the universal healthcare system 
in Australia, the study captures all subsidised antipsychotics 
dispensed in the first 100 days of RACF entry and all deaths 
are captured with the National Death Index.
This is one of few studies which has been able to exam-
ine incident antipsychotic use after moving to residential 
aged care. By starting the study at 100 days post-entry to a 
RACF we have minimised immortal time bias, however, we 
recognise there may be differences in the total amount of 
antipsychotic exposure in the 100 days before study entry 
and we did not assess antipsychotic exposure post-study 
entry [44]. A major strength of the study over some of the 
existing claims-based data studies is the inclusion of clinical 
information including specific resident behavioural symp-
toms and cognitive assessment results that often are lacking 
in claims-based data studies. This meant that we could adjust 
for symptom severity and minimise the risk of confounding.
Table 2  Risk of mortality 
associated with incident 
antipsychotic medication use 
within 100 days after moving to 
a residential aged care facility 
[Hazard ratios (HR) and 95% 
confidence intervals (CI)]
a Adjusted for age and sex
b Adjusted for age, sex, co-morbidity score and activity limitations, verbal and physical behavioural symp-
toms, wandering, depression and cognitive impairment
All-cause mortality Mortality with cerebrovascular 
causes
HR (95% CI)a HR (95% CI)b HR (95% CI)a HR (95% CI)b
All participants (n = 265,820)
 Any antipsychotic 1.31 (1.29, 1.33) 1.22 (1.20, 1.24) 1.33 (1.29, 1.37) 1.17 (1.13, 1.21)
 Typical 1.43 (1.39, 1.48) 1.28 (1.24, 1.33) 1.43 (1.33, 1.54) 1.19 (1.11, 1.28)
 Atypical 1.25 (1.23, 1.28) 1.17 (1.15, 1.19) 1.29 (1.25, 1.34) 1.15 (1.11, 1.19)
 Typical vs. atypical 1.16 (1.12, 1.21) 1.12 (1.08, 1.16) 1.13 (1.05, 1.23) 1.06 (0.98, 1.15)
Dementia (n = 119,665)
 Any antipsychotic 1.27 (1.24, 1.29) 1.20 (1.18, 1.22) 1.19 (1.15, 1.24) 1.15 (1.10, 1.20)
 Typical 1.23 (1.18, 1.29) 1.14 (1.10, 1.20) 1.25 (1.14, 1.37) 1.16 (1.06, 1.27)
 Atypical 1.23 (1.21, 1.25) 1.17 (1.15, 1.19) 1.17 (1.12, 1.22) 1.13 (1.09, 1.18)
 Typical vs. atypical 1.04 (0.99, 1.09) 1.02 (0.97, 1.07) 1.10 (0.99, 1.21) 1.06 (0.96, 1.17)
No dementia (n = 146,155)
 Any antipsychotic 1.39 (1.35, 1.43) 1.28 (1.24, 1.31) 1.63 (1.54, 1.74) 1.30 (1.22, 1.39)
 Typical 1.79 (1.70, 1.89) 1.54 (1.46, 1.63) 1.74 (1.55, 1.96) 1.26 (1.21, 1.42)
 Atypical 1.26 (1.22, 1.30) 1.17 (1.13, 1.21) 1.56 (1.46, 1.67) 1.28 (1.19, 1.37)
 Typical vs. atypical 1.41 (1.33, 1.51) 1.33 (1.25, 1.42) 1.12 (0.98, 1.28) 1.03 (0.90, 1.18)
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There are several limitations to the study. One limita-
tion is that medicines which are supplied to hospital inpa-
tients are not PBS-subsidised and only certain Australian 
hospitals are able to supply PBS-subsidised medicines on 
discharge. Therefore, the first supply of an antipsychotic 
may appear in the 100-day period for residents moving to a 
RACF immediately after a hospital stay where an antipsy-
chotic was commenced. We did not have the indication for 
antipsychotic use, dose or frequency of use so these could 
not be examined in this study. In this study, 4.8% of people 
without a diagnosis of dementia received antipsychotic(s). 
We could not further explore why people without dementia 
were prescribed antipsychotics, but this may be due to 
other severe mental health conditions (e.g. schizophrenia) 
that could not be captured in this dataset as other mental 
health conditions (e.g. depression) are grouped together 
with more severe mental health conditions on aged care 
assessments. This could also indicate off-label and poten-
tially inappropriate use or undiagnosed dementia. Because 
we lacked data on indication and in-hospital use, we were 
also unable to ascertain if the antipsychotic was prescribed 
for short term treatment (e.g. for symptoms of delirium) 
or intended for long-term regular use. With using claims-
based data we do not have information on medication 
adherence, but because the majority of residents require 
assistance with medication management and adminis-
tration from staff, nonadherence is likely to be minor in 
this population, although it is unknown if antipsychotics 
that were dispensed to residents were administered when 
needed or regularly. Finally, because of the observational 
nature of our study, while we have adjusted our risk esti-
mate models for many potential confounding factors of the 
association of antipsychotic use and mortality, there may 
be residual confounding affecting our estimates.
Conclusion
In this nationally representative study of people moving to 
RACFs in Australia, incident antipsychotic use after enter-
ing care was associated with a higher risk of mortality. After 
adjusting for many potential confounding factors, a 20% 
higher risk of mortality for residents with dementia and a 
28% higher risk of mortality for residents without demen-
tia were identified. This adds to the body of evidence to 
suggest prescription of antipsychotics for people moving to 
RACFs should only be considered when the person is at risk 
of harm and/or when other non-pharmacological approaches 
have failed. The results of this study suggest entry to RACFs 
could be a critical time for targeting non-pharmacological 
interventions to support people during their transition to 
aged care to help avoid the use of antipsychotics.
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